SUDA Pharmaceuticals Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, has lodged its appeal with the Australian Therapeutic Goods Administration against the notice of denial for marketing approval of its ArTiMist® oral spray.
For more information, download the attached PDF.
Download this document
